AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3356203 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of subcutaneous histamine and oral H2-antihistaminics (ranitidine or cimetidine)
Number of subjects: 31
Study 3356203 — intervention group
Group type: COMPARATOR
Intervention: Non-treated patients with similar advanced cancer
Number of subjects: 31
Study 31740103 — intervention group
Group type: EXPERIMENTAL
Intervention: GAS-based rehabilitation
Number of subjects: 120
Study 31740103 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation
Number of subjects: 120
Study 31267659 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole brain radiotherapy (WBRT)
Number of subjects: 116
Study 28593326 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (0.5 µg/kg/h) during surgery and up to 2 hours in the recovery room
Number of subjects: 404
Study 28593326 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo infused during surgery and for 2 hours in the recovery room
Number of subjects: 404
Study 28593326 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 404
Study 28593326 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 404
Study 25296533 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost (0.03%)
Number of subjects: 0
Study 23978160 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy-adaptation training
Number of subjects: 0
Study 23978160 — intervention group
Group type: COMPARATOR
Intervention: Strategy training
Number of subjects: 0
Study 23978160 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 0
Study 23978160 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy-adaptation training via manual at home
Number of subjects: 0
Study 21697589 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation Gaming System (RGS)
Number of subjects: 8
Study 21697589 — intervention group
Group type: COMPARATOR
Intervention: Control group (intense occupational therapy or non-specific interactive games)
Number of subjects: 8
Study 19097714 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (1.25 mg/d)
Number of subjects: 80
Study 19097714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 17046475 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting methylprednisolone
Number of subjects: 87
Study 17046475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 15232803 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil, 5 microg/kg with glycopyrrolate, 0.2 mg
Number of subjects: 100
Study 15232803 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl, 20 microg/kg with glycopyrrolate, 0.2 mg
Number of subjects: 100
Study 15232803 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 100
Study 15232803 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 100
Study 15232803 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil and Fentanyl
Number of subjects: 100
Study 11520836 — intervention group
Group type: EXPERIMENTAL
Intervention: Single infusion of 5 mg/kg liposomal amphotericin B (n=46)
Number of subjects: 91
Study 11520836 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily infusions of 1 mg/kg liposomal amphotericin B for five days (n=45)
Number of subjects: 91
Study 9360753 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine (Cyt)
Number of subjects: 1
Study 9360753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 8506455 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 hours time in bed
Number of subjects: 32
Study 8506455 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 hours time in bed
Number of subjects: 32
Study 8506455 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 hours time in bed
Number of subjects: 32
Study 8506455 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 hours time in bed
Number of subjects: 32
Study 3446803 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg oral dose)
Number of subjects: 5
Study 3446803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 30021457 — intervention group
Group type: EXPERIMENTAL
Intervention: ASAP intervention program plus treatment as usual
Number of subjects: 66
Study 30021457 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual alone
Number of subjects: 66
Study 28446496 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth program for 6 months
Number of subjects: 315
Study 26290106 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 2 μg·kg(‐1)·min(‐1) dopamine
Number of subjects: 0
Study 26290106 — intervention group
Group type: COMPARATOR
Intervention: Volume-matched saline (placebo)
Number of subjects: 0
Study 23331565 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual allergen-specific immunotherapy (SLIT) with Staloral 300R, Stallergenes, France
Number of subjects: 111
Study 23331565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 20599004 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 0
Study 20599004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18370886 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive Writing (EW)
Number of subjects: 24
Study 18370886 — intervention group
Group type: COMPARATOR
Intervention: Neutral Writing (NW)
Number of subjects: 24
Study 16987170 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole (100 mg b.i.d.)
Number of subjects: 10
Study 16987170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12733091 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick tests (SPTs) with flour allergens
Number of subjects: 65
Study 12733091 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick tests (SPTs) with alpha-amylase
Number of subjects: 65
Study 12733091 — intervention group
Group type: EXPERIMENTAL
Intervention: Odds ratio for SPT positive to flour or alpha-amylase for asthmatics with onset during bakery work
Number of subjects: 65
Study 12733091 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive predictive value of sensitisation to flour or alpha-amylase
Number of subjects: 65
Study 12733091 — intervention group
Group type: COMPARATOR
Intervention: Indices of airway inflammation
Number of subjects: 65
Study 10631622 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide 1 mg
Number of subjects: 361
Study 10631622 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide 4 mg
Number of subjects: 361
Study 10631622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 361
Study 9186283 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU; 120 mg/d orally for 2 months)
Number of subjects: 37
Study 9186283 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 37
Study 1488998 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous rHuEPO (150 U/kg/week in three divided doses)
Number of subjects: 128
Study 1488998 — intervention group
Group type: COMPARATOR
Intervention: Intravenous rHuEPO (150 U/kg/week in three divided doses)
Number of subjects: 128
Study 1488998 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (subcutaneous and intravenous)
Number of subjects: 128
Study 3706388 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight individuals (more than 40 percent overweight)
Number of subjects: 0
Study 3706388 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly diabetic patients (50 years of age or older)
Number of subjects: 0
Study 3706388 — intervention group
Group type: COMPARATOR
Intervention: Normal weight individuals
Number of subjects: 0
Study 30460454 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype marathon racing shoes (NP)
Number of subjects: 10
Study 30460454 — intervention group
Group type: COMPARATOR
Intervention: Nike Zoom Streak 6 (NS)
Number of subjects: 10
Study 30460454 — intervention group
Group type: COMPARATOR
Intervention: adidas adizero Adios BOOST 2 (AB)
Number of subjects: 10
Study 30361406 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP point-of-care tests (POCTs)
Number of subjects: 26
Study 30361406 — intervention group
Group type: COMPARATOR
Intervention: Control practices (not offered CRP POCT)
Number of subjects: 26
Study 27870694 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrasession concurrent aerobic before strength training (GAS: n = 39)
Number of subjects: 128
Study 27870694 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrasession concurrent aerobic after strength training (GSA: n = 45)
Number of subjects: 128
Study 27870694 — intervention group
Group type: COMPARATOR
Intervention: Control group (GC: n = 44; no training program)
Number of subjects: 128
Study 24468428 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenbendazole treatment group (623 cows)
Number of subjects: 1254
Study 24468428 — intervention group
Group type: COMPARATOR
Intervention: Control group (631 cows)
Number of subjects: 1254
Study 21193295 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised intensive lifestyle intervention
Number of subjects: 59
Study 21193295 — intervention group
Group type: COMPARATOR
Intervention: Routine lifestyle advice (Control)
Number of subjects: 59
Study 20430240 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 194
Study 20430240 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 194
Study 17999782 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 200 microg
Number of subjects: 39
Study 17999782 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 1000 microg
Number of subjects: 39
Study 17999782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 17999782 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 50 microg
Number of subjects: 39
Study 17999782 — intervention group
Group type: COMPARATOR
Intervention: Salmabutamol 200 microg
Number of subjects: 39
Study 17999782 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 250 microg
Number of subjects: 39
Study 15305160 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide plus docetaxel
Number of subjects: 25
Study 15305160 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide plus cisplatin
Number of subjects: 25
Study 15305160 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide as single agent
Number of subjects: 25
Study 15305160 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide-based chemotherapy (all groups)
Number of subjects: 25
Study 11641669 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin administration before placental delivery
Number of subjects: 1486
Study 11641669 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin administration after placental delivery
Number of subjects: 1486
Study 9852693 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus administration of mexiletine 2 mg.kg‐1
Number of subjects: 28
Study 9852693 — intervention group
Group type: COMPARATOR
Intervention: Bolus administration of mexiletine 1 mg.kg‐1 with continuous administration of 1 mg.kg‐1.hr‐1 for 75 minutes
Number of subjects: 28
Study 9852693 — intervention group
Group type: COMPARATOR
Intervention: No mexiletine administration
Number of subjects: 28
Study 8276350 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock‐wave lithotripsy followed by methyl tert‐butyl ether dissolution
Number of subjects: 50
Study 8276350 — intervention group
Group type: COMPARATOR
Intervention: Methyl tert‐butyl ether alone
Number of subjects: 50
Study 8276350 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock‐wave lithotripsy and methyl tert‐butyl ether dissolution
Number of subjects: 50
Study 8276350 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock‐wave lithotripsy and methyl tert‐butyl ether
Number of subjects: 50
Study 2609736 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide
Number of subjects: 60
Study 2609736 — intervention group
Group type: COMPARATOR
Intervention: Glucagon
Number of subjects: 60
Study 30760509 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab (15 mg/kg)
Number of subjects: 420
Study 30760509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study 30760509 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 420
Study 28099357 — intervention group
Group type: EXPERIMENTAL
Intervention: bilayered negative pressure wound therapy (b‐NPWT) applied to thigh incision for 5 days
Number of subjects: 72
Study 28099357 — intervention group
Group type: COMPARATOR
Intervention: Traditional surgical pads applied to control thigh and control shank incisions
Number of subjects: 72
Study 26581899 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 60
Study 26581899 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary Behavior (SB)
Number of subjects: 60
Study 26581899 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory Fitness (CRF)
Number of subjects: 60
Study 26581899 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue, Age, Fat Mass, Cancer Treatment Status
Number of subjects: 60
Study 26581899 — intervention group
Group type: EXPERIMENTAL
Intervention: CRF
Number of subjects: 60
Study 24152215 — intervention group
Group type: EXPERIMENTAL
Intervention: cFIR neck device for 1 week
Number of subjects: 48
Study 24152215 — intervention group
Group type: COMPARATOR
Intervention: Control (sham-treatment) group with inert neck device for 1 week
Number of subjects: 48
Study 22265220 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal irrigation with a solution of 240 mg gentamicin and 600 mg clindamycin
Number of subjects: 103
Study 22265220 — intervention group
Group type: COMPARATOR
Intervention: Intra-abdominal irrigation with normal saline
Number of subjects: 103
Study 21126374 — intervention group
Group type: EXPERIMENTAL
Intervention: Consideration of extremely good health state descriptors (Description-A)
Number of subjects: 151
Study 21126374 — intervention group
Group type: EXPERIMENTAL
Intervention: Consideration of extremely poor health state descriptors (Description-B)
Number of subjects: 151
Study 21126374 — intervention group
Group type: COMPARATOR
Intervention: Consideration of best health VAS anchor
Number of subjects: 151
Study 17402993 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha2a (40 kDa) 180 microg/week plus ribavirin 1000/1200 mg/day for 48 weeks
Number of subjects: 475
Study 15806621 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy regimen 1
Number of subjects: 0
Study 15806621 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy regimen 2
Number of subjects: 0
Study 15806621 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive randomization procedure
Number of subjects: 0
Study 15806621 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-stage chemotherapy
Number of subjects: 0
Study 12096303 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using photosensitizers activated by light
Number of subjects: 0
Study 12096303 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PDT with other established modalities
Number of subjects: 0
Study 12096303 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of photosensitizers for endoscopic diagnosis and treatment guidance
Number of subjects: 0
Study 9802531 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.56 g/kg)
Number of subjects: 30
Study 9802531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9593798 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin cream (1.5 g, 1%) applied for 15 min
Number of subjects: 10
Study 9593798 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied for 15 min
Number of subjects: 10
Study 1897303 — intervention group
Group type: EXPERIMENTAL
Intervention: PFHSP70 antigen
Number of subjects: 0
Study 1897303 — intervention group
Group type: EXPERIMENTAL
Intervention: Total schizont antigens
Number of subjects: 0
Study 1897303 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-responsiveness to PFHSP70
Number of subjects: 0
Study 6614638 — intervention group
Group type: EXPERIMENTAL
Intervention: H2SO4 and NH4HSO4 at 1,000 micrograms/m3
Number of subjects: 17
Study 6614638 — intervention group
Group type: EXPERIMENTAL
Intervention: H2SO4 at 450 micrograms/m3
Number of subjects: 17
Study 6614638 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (NaCl) aerosol
Number of subjects: 17
Study 31189338 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Interpersonal Counseling (TIPC)
Number of subjects: 241
Study 31189338 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive Health Education (SHE)
Number of subjects: 241
Study 30528315 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 100 mg/day
Number of subjects: 60
Study 30528315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30528315 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire cohort (Cabozantinib and Placebo)
Number of subjects: 60
Study 28935146 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate (65 g, 2148 mg polyphenols)
Number of subjects: 92
Study 28935146 — intervention group
Group type: COMPARATOR
Intervention: Placebo chocolate (without polyphenols)
Number of subjects: 92
Study 28935146 — intervention group
Group type: EXPERIMENTAL
Intervention: Mate tea (3 g, 107 mg total phenols, 84.24 mg chlorogenic acid)
Number of subjects: 92
Study 28935146 — intervention group
Group type: COMPARATOR
Intervention: Placebo mate (without polyphenols)
Number of subjects: 92
Study 26794189 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer liner (Glass Liner II)
Number of subjects: 39
Study 26794189 — intervention group
Group type: COMPARATOR
Intervention: No lining (control group)
Number of subjects: 39
Study 26794189 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (lined and unlined)
Number of subjects: 39
Study 26813555 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-time SBPV group (2,279 participants)
Number of subjects: 2464
Study 26813555 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-time SBPV group (1,636 participants)
Number of subjects: 2464
Study 26813555 — intervention group
Group type: EXPERIMENTAL
Intervention: Long- plus short-time SBPV group (1,632 participants)
Number of subjects: 2464
Study 26813555 — intervention group
Group type: EXPERIMENTAL
Intervention: Day time SBPV increase
Number of subjects: 2464
Study 24152796 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 38
Study 24152796 — intervention group
Group type: COMPARATOR
Intervention: Placebo CPAP
Number of subjects: 38
Study 21802921 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivy leaves soft extract
Number of subjects: 590
Study 21802921 — intervention group
Group type: COMPARATOR
Intervention: Other ivy leaves extract
Number of subjects: 590
Study 18806764 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL apheresis (LA) combined with conventional therapy (CT)
Number of subjects: 20
Study 18806764 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (CT) only
Number of subjects: 20
Study 16394045 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG plus prednisone
Number of subjects: 78
Study 16394045 — intervention group
Group type: COMPARATOR
Intervention: IVIG alone
Number of subjects: 78
Study 16394045 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 78
Study 16394045 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal blood sampling procedures
Number of subjects: 78
Study 15161800 — intervention group
Group type: EXPERIMENTAL
Intervention: 32-33 split proinsulin
Number of subjects: 667
Study 15161800 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact proinsulin
Number of subjects: 667
Study 15161800 — intervention group
Group type: EXPERIMENTAL
Intervention: Early insulin response (EIR)
Number of subjects: 667
Study 15161800 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitivity index (S(i))
Number of subjects: 667
Study 12968768 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 0
Study 10538481 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiral computed tomography (spiral CT) for lung cancer screening
Number of subjects: 0
Study 7659484 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccines
Number of subjects: 15
Study 7659484 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole‐cell vaccines
Number of subjects: 15
Study 7659484 — intervention group
Group type: EXPERIMENTAL
Intervention: One vaccine without detectable FIM
Number of subjects: 15
Study 2695280 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg bd (n = 6)
Number of subjects: 12
Study 2695280 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 12
Study 568870 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP (desamino-D-arginine vasopressin, Minirin) 20 micrograms intranasally at bedtime
Number of subjects: 18
Study 30961440 — intervention group
Group type: EXPERIMENTAL
Intervention: 15/40 (15% 1RM with 40% arterial occlusion pressure)
Number of subjects: 0
Study 30961440 — intervention group
Group type: EXPERIMENTAL
Intervention: 15/80 (15% 1RM with 80% arterial occlusion pressure)
Number of subjects: 0
Study 30961440 — intervention group
Group type: COMPARATOR
Intervention: 15/0 (15% 1RM without blood flow restriction)
Number of subjects: 0
Study 30961440 — intervention group
Group type: COMPARATOR
Intervention: 70/0 (traditional high load resistance exercise)
Number of subjects: 0
Study 30961440 — intervention group
Group type: EXPERIMENTAL
Intervention: 15/40 and 15/80 (upper body conditions)
Number of subjects: 0
Study 28225315 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative interventions including standardized insulin infusion protocols, hypoglycemia prevention bundles, audit and feedback, education, and measure‐vention
Number of subjects: 9
Study 28225315 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative interventions
Number of subjects: 9
Study 26439577 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomilla L., Melissa Officinalis L. and tyndallized Lactobacillus Acidophilus (H122) (Group A; n = 45)
Number of subjects: 133